Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2671-2681

  Goldberger, Natalie ^a   Walker, Renard C ^a   Kim, Chang Hee ^a   Winter, Scott ^a   Hunter, Kent W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MICRORNA; MICRORNA 290; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARID4B GENE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; IN VIVO STUDY; METASTASIS; METASTATIC LATENCY; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR LATENCY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UPREGULATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; MICE; MICE, TRANSGENIC; MICRORNAS; NEOPLASM METASTASIS; PHENOTYPE; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84876912041     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3513     Document Type: Article

References (50)

1. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res 2008;10 Suppl 1:S2.
2. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006;8:R16.
3. Crawford NP, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, et al. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci U S A 2008;105:6380-5.
4. Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, et al. Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 2007;3:e214.
5. Hsieh SM, Lintell NA, Hunter KW. Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer. Breast Dis 2006;26:157-62.
6. Ambros V. The functions of animal microRNAs. Nature 2004;431: 350-5.
7. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 2005;132:4653-62.
8. Kent OA, Mendell JT. A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene 2006;25:6188-96.
9. Shenouda SK, Alahari SK. MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78.
10. Calin GA, Croce CM. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 2006;66:7390-4.
11. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009;9:293-302.
12. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
13. de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S, et al. Germline deletion of the miR-17 approximately 92 cluster causes skeletal and growth defects in humans. Nat Genet 2011;43:1026-30.
14. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353: 1793-801.
15. Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 2009;46:358-60.
16. Hunter KW, Broman KW, Voyer TL, Lukes L,Cozma D, Debies MT, et al. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 2001;61:8866-72.
17. Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG, et al. MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat Struct Mol Biol 2008;15:259-67.
18. Houbaviy HB, Dennis L, Jaenisch R, Sharp PA. Characterization of a highly variable eutherian microRNA gene. RNA 2005;11:1245-57.
19. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. Dev Cell 2003;5:351-8.
20. Winter SF, Lukes L, Walker RC, Welch DR, Hunter KW. Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis. PLoS Genet 2012;8:e1002735.
21. Mucenski ML, Taylor BA, Jenkins NA, Copeland NG. AKXD recombinant inbred strains: Models for studying the molecular genetic basis of murine lymphomas. Mol Cell Biol 1986;6:4236-43.
22. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
24. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, et al. FVB/N: An inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A 1991;88:2065-9.
25. Cao J, Gao T, Stanbridge EJ, Irie R. RBP1L1, a retinoblastoma-binding protein-related gene encoding an antigenic epitope abundantly expressed in human carcinomas and normal testis. J Natl Cancer Inst 2001;93:1159-65.
26. Cui D, Jin G, Gao T, Sun T, Tian F, Estrada GG, et al. Characterization of BRCAA1 and its novel antigen epitope identification. Cancer Epidemiol Biomarkers Prev 2004;13:1136-45.
27. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissuespecific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276:11252-6.
28. White RT, Damm D, Hancock N, Rosen BS, Lowell BB, Usher P, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 1992;267:9210-3.
29. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.
30. Peake PW, Shen Y, Campbell LV, Charlesworth JA. Human adiponectin binds to bacterial lipopolysaccharide. Biochem Biophys Res Commun 2006;341:108-15.
31. Yang RY, Hsu DK, Yu L, Chen HY, Liu FT. Galectin-12 is required for adipogenic signaling and adipocyte differentiation. J Biol Chem 2004;279:29761-6.
32. Tang X, Xing Z, Tang H, Liang L, Zhao M. Human cell-death-inducing DFF45-like effector C induces apoptosis via caspase-8. Acta Biochim Biophys Sin 2011;43:779-86.
33. Cardamone MD, Bardella C, Gutierrez A, Di Croce L, Rosenfeld MG, Di Renzo MF, et al. ERalpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A 2009;106:7420-5.
34. Leunen K, Gevaert O, Daemen A, Vanspauwen V, Michils G, De Moor B, et al. Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways. Hum Mutat 2009;30: 1693-702.
35. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003;95:1597-608.
36. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003;95:1586-97.
37. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998;77:640-4.
38. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449: 682-8.
39. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007;72:7-25.
40. Osipo C, Liu H, Meeke K, Jordan VC. The consequences of exhaustive antiestrogen therapy in breast cancer: Estrogen-induced tumor cell death. Exp Biol Med (Maywood) 2004;229:722-31.
41. Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2003;2:205-13.
42. Haddow A, Watkinson JM, Paterson E, Koller PC. Influence of synthetic oestrogens on advanced malignant disease. Br Med J 1944;2: 393-8.
43. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111-6.
44. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4:133-6.
45. Gu P, Reid JG, Gao X, Shaw CA, Creighton C, Tran PL, et al. Novel microRNA candidates and miRNA-mRNA pairs in embryonic stem (ES) cells. PLoS One 2008;3:e2548.
46. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008;134:521-33.
47. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141-6.
48. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008;133:1106-17.
49. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009;460:1136-9.
50. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Mycregulated microRNAs modulate E2F1 expression. Nature 2005;435: 839-43.